The Alzheimer’s Paradox: Early Diagnosis Is Here. Effective Treatment Isn’t
The first drugs that change the disease

For decades, Alzheimer’s treatments focused on managing symptoms. Medications such as donepezil could temporarily improve memory and cognitive function, but they did little to address the underlying biological processes destroying brain cells. That began to change with the arrival of lecanemab and donanemab, two monoclonal antibody drugs designed to remove amyloid-beta plaques from the brain. These protein deposits are one of the defining features of Alzheimer’s pathology and have been a central target of research for decades.
Both drugs demonstrated an ability to slow cognitive decline in large Phase 3 clinical trials. Lecanemab reduced the rate of decline by 27% over 18 months compared with placebo. Donanemab also produced significant results, with approximately 22–35% slowing depending on the patient group and cognitive measure used. In practical terms, researchers have estimated the difference as several months of delayed progression over the treatment period.
These are genuine disease-modifying treatments: they intervene in the biological mechanisms of Alzheimer’s rather than simply treating its symptoms. But their limitations are substantial. Both drugs are intended for patients in the early stages of the disease, before extensive neurological damage has occurred. They also carry the risk of amyloid-related imaging abnormalities (ARIA), which can cause brain swelling and microbleeds, sometimes with serious consequences. Treatment requires regular infusions, repeated MRI scans, and careful medical supervision.